DOCSLIB.ORG

CTRI Trial Data

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CTRI Trial Data PDF of Trial CTRI Website URL - http://ctri.nic.in Clinical Trial Details (PDF Generation Date :- Sat, 25 Sep 2021 19:48:28 GMT) CTRI Number CTRI/2012/02/002417 [Registered on: 13/02/2012] - Trial Registered Prospectively Last Modified On 28/02/2013 Post Graduate Thesis No Type of Trial Interventional Type of Study Drug Study Design Randomized, Parallel Group, Placebo Controlled Trial Public Title of Study A clinical trial comparing the safety and effectiveness of hexylresorcinol lozenges and combination product of hexyl resorcinol and benzalkonium chloride against placebo in relieving throat pain due to upper respiratory tract infection Scientific Title of A randomized, double blind, parallel group study comparing the Efficacy and Safety of Study Hexylresorcinol 2.4 mg lozenges and FDC of Hexylresorcinol 2.5 mg and Benzalkonium chloride 1.2 mg Lozenges with demulcent placebo lozenges in relieving pain of sore throat due to upper respiratory tract infection Secondary IDs if Any Secondary ID Identifier LA/80/2010 Protocol Number Details of Principal Details of Principal Investigator Investigator or overall Name Dr Balasubramanyam Trial Coordinator (multi-center study) Designation Professor & Head Unit II Affiliation St Johns Medical College Address St Johns Medical College Hospital, Sarjapur Main Road, Koramangala, Bangalore Bangalore KARNATAKA 560034 India Phone 09341229263 Fax Email [email protected] Details Contact Details Contact Person (Scientific Query) Person (Scientific Name Dr Sandhya Ravi Query) Designation Director Operations Affiliation Lotus Clinical Research Academy Pvt Ltd Address Lotus Clinical Research Academy Pvt. Ltd. 147/F || 8th Main || 3rd Block || Koramangala || Bangalore - 560 034. Karnataka. INDIA. Bangalore KARNATAKA 560034 India Phone 09845017452 Fax Email [email protected] Details Contact Details Contact Person (Public Query) Person (Public Query) Name Dr Balasubramanyam Designation Professor & Head Unit II Affiliation St Johns Medical College Address St Johns Medical College Hospital, Sarjapur Main Road, Koramangala, Bangalore Bangalore KARNATAKA page 1 / 5 PDF of Trial CTRI Website URL - http://ctri.nic.in 560034 India Phone 09341229263 Fax Email [email protected] Source of Monetary or Source of Monetary or Material Support Material Support > Remedia Therapeutics Private Limited Primary Sponsor Primary Sponsor Details Name Remedia Therapeutics Private Limited Address Office No.1, 3rd Floor, Karmali Glass Towers, Opp. to Traffic Police Cell, S.V. Road, Panjim, Goa - 403 001 Type of Sponsor Pharmaceutical industry-Indian Details of Secondary Name Address Sponsor Lotus Clinical Research Academy 147/F,8th Main, 3rd Block, Koramangala Bangalore 560034 Countries of List of Countries Recruitment India Sites of Study Name of Principal Name of Site Site Address Phone/Fax/Email Investigator Dr Ramesh Chandra Arogya Multispecialty first floor,Near Unity 9844145770 Sahoo Clinic hospital, Falnir Road, Mangalore- 575002 [email protected] Dakshina Kannada KARNATAKA Dr Balakrishnan D Dr.Balakrishnan Private private clinic,No-6,16th 09841910001 Clinic cross street, Indiranagar, [email protected] Chennai-600020 Chennai TAMIL NADU Dr Atul Joshi Sahyadri Hospital Ltd Department of Internal 9822430776 medicine,30C Erandwane, Karve [email protected] Road, Pune – 411004 om Pune MAHARASHTRA Dr Balasubramanyam St Johns Medical ENT department, Room 09341229263 College Hospital No.27,Sarjapur Main Road, Koramangala, [email protected] Bangalore – 560034 Bangalore KARNATAKA Dr Sandeep Nayak Uma Clinic Private 9845582363 clinic,No-1474/2, Kodigehalli circle, [email protected] Sahakarnagar post Bangalore-5600092 Bangalore KARNATAKA Details of Ethics Name of Committee Approval Status Date of Approval Is Independent Ethics Committee Committee? DrBalakrishnanD/Natio Approved 27/01/2012 Yes nalEthicscommittee/Ch ennai page 2 / 5 PDF of Trial CTRI Website URL - http://ctri.nic.in DrAtulJoshi/Sahyadriho Approved 16/04/2012 No spitalethicscommittee/P une DrBalasubramanyam/In Approved 14/02/2012 No stitutionalethicalreviewB oard/Bangalore DrRameshChandraSah Approved 25/02/2012 Yes oo/MallikattaEthicalCo mmittee/Mangalore DrSandeepNayak/IECC Approved 12/01/2012 Yes onsultantsDarussalam/ Koramangala/Bangalor e Regulatory Clearance Status Date Status from DCGI Approved/Obtained 07/12/2011 Health Condition / Health Type Condition Problems Studied Patients Sore Throat due to Upper Respiratory Tract Infection Intervention / Type Name Details Comparator Agent Intervention Hexylresorcinol 2.4 mg Mode of administration is One lozenges and FDC of lozenge to be dissolved slowly Hexylresorcinol 2.5 mg and in the mouth Subjects are Benzalkonium chloride 1.2 mg instructed to take, if required, a Lozenges maximum of 6 lozenges within a 24 hour period Hexyl resorcinol 2.4mg and FDC of Hexyl Resorcinal 2.5 mg and benzalkonium chloride 1.2 mg Duration of therapy is 3 days Comparator Agent Demulcent placebo lozenges Mode of administration is One lozenge to be dissolved slowly in the mouth Subjects are instructed to take, if required, a maximum of 6 lozenges within a 24 hour period and duration of therapy is 3 days Inclusion Criteria Inclusion Criteria Age From 18.00 Year(s) Age To 80.00 Year(s) Gender Both Details 1. Patients having sore throat associated with upper respiratory tract infection, diagnosed clinically as pharyngitis.<br/> 2. Female and male patients between the age of 18 and 80 years (inclusive of both).<br/> 3. Willing to give written informed consent.<br/> 4. The throat pain intensity is rated as at least moderate on the Verbal Rating scale (VRS) by the patient.<br/> 5. Compliance by the patient seems guaranteed, and patient seems to be able to understand and complete the subject diary card.<br/> 6. Willing to remain at the doctors practice for the initial 3 hours following the first intake of study medication or willing to comply with the documentation requirement of completing the subject diary card.<br/> 7. Willing to return for the end of study visit. Exclusion Criteria Exclusion Criteria Details 1. Patients with symptoms of primary bacterial pharyngitis or bacterial secondary infection as assessed clinically. page 3 / 5 PDF of Trial CTRI Website URL - http://ctri.nic.in 2. First indication of symptoms of acute pharyngitis (e.g. sore throat) occurred more than 2 days ago. 3. Patients who in the past week required antibiotics for sore throat associated with upper respiratory tract infection. 4. Patients who in the past week required or during the study will require treatment with any of the following: steroids for oral, inhaling or topical application, expectorants or antitussives. 5. Patients who have used lozenges or any other topical throat treatment 2 hours prior to the screening, any sore throat medication containing a local anesthetic 04 hours prior to the screening, any short acting analgesic 6 hours prior to the screening and any long acting or slow-release analgesic 24 hours prior to the screening. 6. Female patients of child-bearing potential who are pregnant or currently breast feeding, or not practicing an acceptable method of birth control. 7. History of fructose intolerance or any metabolic disorder relating to glucose / sucrose ingestion. 8. Patients with known diabetes mellitus. 9. Patients with mouth breathing as a result of nasal congestion. 10. Known hypersensitivity to hexylresorcinol or benzalkonium chloride or any auxiliary substances contained in the lozenges. 11. Any existing malignancy. 12. Chronic smokers, tobacco chewers, alcoholics and those with a history of drug abuse. 13. Any clinical condition which, in the opinion of the investigator would not allow safe completion of the study and safe administration of study medication. 14. Patients who will be unable to comply fully with the protocol requirements. 15. Any investigational therapy within 30 days prior to randomization into this study. 16. Patients who are unable to comply with documentation required in the diary card for the study. Method of Generating Computer generated randomization Random Sequence Method of Sequentially numbered, sealed, opaque envelopes Concealment Blinding/Masking Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded Primary Outcome Outcome Timepoints Pain intensity difference from pre-dose baseline Pain intensity difference from pre-dose baseline as rated on a 6 point VRS by the patients at 0.5, as rated on a 6 point VRS by the patients at 0.5, 01, 02 and 03 hours after the first lozenge. 01, 02 and 03 hours after the first lozenge. Secondary Outcome Outcome Timepoints Time to onset of action (action defined as the Time to onset of action (action defined as the first notification of change in 06 point VRS first notification of change in 06 point VRS towards mild) after the first lozenge. towards mild) after the first lozenge. Change from baseline in the difficulty in Change from baseline in the difficulty in swallowing as rated on the Wong Baker Faces swallowing as rated on the Wong Baker Faces Pain Rating Scale by the patient at 0.5, 01, 02 Pain Rating Scale by the patient at 0.5, 01, 02 and 03 hours after the first lozenge. and 03 hours after the first lozenge. Final global assessment of efficacy (pain relief) Final global assessment of efficacy (pain relief) by the patient. by the patient. (Day 03) Target Sample Size Total Sample Size=120 Sample Size from India=120 Final Enrollment numbers achieved (Total)= Final Enrollment numbers achieved (India)= Phase of Trial Phase 3 page
Load more

Recommended publications
  • Tonsillopharyngitis - Acute (1 of 10)
    Tonsillopharyngitis - Acute (1 of 10) 1 Patient presents w/ sore throat 2 EVALUATION Yes EXPERT Are there signs of REFERRAL complication? No 3 4 EVALUATION Is Group A Beta-hemolytic Yes DIAGNOSIS Streptococcus (GABHS) • Rapid antigen detection test infection suspected? (RADT) • roat culture No TREATMENT EVALUATION No A Supportive management Is GABHS confi rmed? B Pharmacological therapy (Non-GABHS) Yes 5 TREATMENT A EVALUATE RESPONSEMIMS Supportive management TO THERAPY C Pharmacological therapy • Antibiotics Poor/No Good D Surgery, if recurrent or complicated response response REASSESS PATIENT COMPLETE THERAPY & REVIEW THE DIAGNOSIS© Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B269 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (2 of 10) 1 ACUTE TONSILLOPHARYNGITIS • Infl ammation of the tonsils & pharynx • Etiologies include bacterial (group A β-hemolytic streptococcus, Haemophilus infl uenzae, Fusobacterium sp, etc) & viral (infl uenza, adenovirus, coronavirus, rhinovirus, etc) pathogens • Sore throat is the most common presenting symptom in older children TONSILLOPHARYNGITIS 2 EVALUATION FOR COMPLICATIONS • Patients w/ sore throat may have deep neck infections including epiglottitis, peritonsillar or retropharyngeal abscess • Examine for signs of upper airway obstruction Signs & Symptoms of Sore roat w/ Complications • Trismus • Inability to swallow liquids • Increased salivation or drooling • Peritonsillar edema • Deviation of uvula
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Quantitative Assessment of Antimicrobial Activity of PLGA Films Loaded with 4-Hexylresorcinol
    Journal of Functional Biomaterials Article Quantitative Assessment of Antimicrobial Activity of PLGA Films Loaded with 4-Hexylresorcinol Michael Kemme * and Regina Heinzel-Wieland Department of Chemical Engineering and Biotechnology, Hochschule Darmstadt, University of Applied Sciences, Stephanstrasse 7, 64295 Darmstadt, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-6151-1638631 Received: 18 December 2017; Accepted: 9 January 2018; Published: 11 January 2018 Abstract: Profound screening and evaluation methods for biocide-releasing polymer films are crucial for predicting applicability and therapeutic outcome of these drug delivery systems. For this purpose, we developed an agar overlay assay embedding biopolymer composite films in a seeded microbial lawn. By combining this approach with model-dependent analysis for agar diffusion, antimicrobial potency of the entrapped drug can be calculated in terms of minimum inhibitory concentrations (MICs). Thus, the topical antiseptic 4-hexylresorcinol (4-HR) was incorporated into poly(lactic-co-glycolic acid) (PLGA) films at different loadings up to 3.7 mg/cm2 surface area through a solvent casting technique. The antimicrobial activity of 4-HR released from these composite films was assessed against a panel of Gram-negative and Gram–positive bacteria, yeasts and filamentous fungi by the proposed assay. All the microbial strains tested were susceptible to PLGA-4-HR films with MIC values down to 0.4% (w/w). The presented approach serves as a reliable method in screening and quantifying the antimicrobial activity of polymer composite films. Moreover, 4-HR-loaded PLGA films are a promising biomaterial that may find future application in the biomedical and packaging sector.
    [Show full text]
  • AP76: 4-Hexyl-Resorcinol CAS#: 136-77-6
    the art and science of smart patch testingTM AP76: 4-hexyl-resorcinol CAS#: 136-77-6 Patient Information Your patch test result indicates that you have a contact allergy to 4-hexyl- resorcinol. This contact allergy may cause your skin to react when it is exposed to this substance although it may take several days for the symptoms to appear. Typical symptoms include redness, swelling, itching, and fluid-filled blisters. Where is 4-hexyl-resorcinol found? 4-hexyl-resorcinol has a long history of human pharmaceutical use as a topical skin and mucosal disinfectant for treatment of superficial wounds, and as a component of soaps, handwashes, and skin cleaners. 4-hexyl-resorcinol has been used in dilute solutions as antiseptic gargles or throat spray, and in lozenges. 4-hexyl-resorcinol is still marketed today as an ingredient of certain throat lozenges. How can you avoid contact with 4-hexyl-resorcinol? Avoid products that list any of the following names in the ingredients: 1,3-Benzenediol, 4-hexyl- Cystoids anthelmintic 1,3-Dihydroxy-4-hexylbenzene EINECS 205-257-4 1,3-Dihydroxy-4-n-hexylbenzene Gelovermin 4-(1-Hexyl)resorcinol Hexylresorcin [German] 4-06-00-06048 (Beilstein Handbook Ref) Hexylresorcinol 4-Hexyl-1,3-benzenediol Hexylresorcinolum 4-Hexyl-1,3-dihydroxybenzene Hexylresorzin 4-Hexylresorcine Hidesol 4-n-Hexylresorcinol HSDB 566 Adrover NCI-C55787 AI3-08055 NSC 1570 Antascarin Oxana Ascaricid p-Hexylresorcinol Ascarinol Prensol Ascaryl Resorcinol, 4-hexyl- BRN 2048312 S.T. 37 Caprokol ST 37 CCRIS 888 ST-37 Crystoids Worm-agen What are some products that may contain 4-hexyl-resorcinol? Cosmetics: Clearasil Adult Care Lotions and Skin Care: KOPNOL Mouthwash / Gargle Throat Lozenges: Sucrets Throat Spray *For additional information about products that might contain 4-hexyl-resorcinol, go to the Household Product Database online (http:/householdproducts.nlm.nih.gov) at the United States National Library of Medicine.
    [Show full text]
  • Sore Throat in Primary Care Project
    Family Practice, 2015, Vol. 32, No. 3, 263–268 doi:10.1093/fampra/cmv015 Advance Access publication 25 March 2015 Epidemiology Sore throat in primary care project: a clinical score to diagnose viral sore throat Selcuk Mistika,*, Selma Gokahmetoglub, Elcin Balcic, and Fahri A Onukd Downloaded from https://academic.oup.com/fampra/article-abstract/32/3/263/695324 by guest on 31 July 2019 aDepartment of Family Medicine, bDepartment of Microbiology, cDepartment of Public Health, Erciyes University Medical Faculty, Kayseri, Turkey, and dBunyamin Somyurek Family Medicine Centre, Kayseri, Turkey. *Correspondence to Prof. S. Mistik, Department of Family Medicine, Erciyes University Medical Faculty, Kayseri 38039, Turkey; E-mail: [email protected] Abstract Objective. Viral agents cause the majority of sore throats. However, there is not currently a score to diagnose viral sore throat. The aims of this study were (i) to find the rate of bacterial and viral causes, (ii) to show the seasonal variations and (iii) to form a new scoring system to diagnose viral sore throat. Methods. A throat culture for group A beta haemolytic streptococci (GABHS) and a nasopharyngeal swab to detect 16 respiratory viruses were obtained from each patient. Over a period of 52 weeks, a total of 624 throat cultures and polymerase chain reaction analyses were performed. Logistic regression analysis was performed to find the clinical score. Results. Viral infection was found in 277 patients (44.3%), and GABHS infection was found in 116 patients (18.5%). An infectious cause was found in 356 patients (57.1%). Rhinovirus was the most commonly detected infectious agent overall (highest in November, 34.5%), and the highest GABHS rate was in November (32.7%).
    [Show full text]
  • Quality Standards Body Care Ingredients Generated on May 5, 2014
    Whole Foods Market - Quality Standards Body Care Ingredients Generated on May 5, 2014 This document is intended for internal company use to assist WFM buyers in making purchasing decisions. Products that do not meet the ingredient standards of this document may not be sold within the product category noted above at Whole Foods Market. We reserve the right to add or remove ingredient terms from the quality standards list or to change the acceptable/unacceptable status of any ingredient at any time. For more information about using these lists, please see http://rock.wholefoods.com/?p=1034. Please make sure that you are using a recently updated list; current quality standards lists are available from the Quality Standards website at http://connect/global/qshe/qualitystandards/food. If you have any questions about this list, please contact the quality standards team at [email protected]. Acceptable and unacceptable ingredients for regular (not premium) body care products. Item Name Type Status Qualifier Functions C12-15 alkyl lactate Body Care acceptable surfactant Glyceryl stearate citrate Body Care acceptable emollient 1,2 hexanediol Body Care acceptable solvent 2-carboxy-1methylpyridinium chloride Body Care acceptable skin conditioning agent 2-propanone Body Care acceptable In nail polish remover only solvent AA2G-Ascorbyl Glucoside Body Care acceptable skin lightener, antioxidant Acacia Decurrens/Jojoba/Sunflower Body Care acceptable texturizer Seed Wax/Polyglyceryl - 3 Esters acetamide MEA Body Care acceptable surfactant acetone
    [Show full text]
  • Randomised, Double-Blind, Placebo-Controlled Study of A
    J Pharm Pharmaceut Sci (www.cspsCanada.org) 15(2) 281 - 294, 2012 Randomised, Double-Blind, Placebo-Controlled Study of a Single Dose of an Amylmetacresol/2,4-dichlorobenzyl Alcohol Plus Lidocaine Lozenge or a Hexylresorcinol Lozenge for the Treatment of Acute Sore Throat Due to Upper Respiratory Tract Infection Damien McNally,1 Adrian Shephard,2 Emma Field3 1 Ormeau Health Centre, Belfast, UK; 2 Professional Relations, Reckitt Benckiser, Slough, UK; 3 Global Medical Affairs, Reckitt Benckiser Healthcare, Hull, UK. Received, January 31, 2012; Revised, February 24, 2012; Accepted, April 1, 2012; Published, April 2, 2012. ABSTRACT - Purpose: Sore throat is a frequent reason for seeking medical care but few prescription options are available. Lozenges are effective in delivering active ingredients to the throat. This study was conducted to determine the analgesic efficacy of two lozenges one containing amylmetacresol (AMC)/2,4- dichlorobenzyl alcohol (DCBA) and lidocaine and one containing hexylresorcinol versus placebo in patients with acute sore throat due to upper respiratory tract infection (URTI). Methods: This was a multicentre, randomised, double-blind, parallel group, placebo-controlled study. In total, 190 patients were randomised 1:1:1 to a single dose of AMC/DCBA + lidocaine, hexylresorcinol or placebo lozenge. Subjective ratings of throat soreness, difficulty swallowing, swollen throat, numbing, and sore throat relief were obtained up to 2 hours post dose. Patient and investigator global ratings and a consumer questionnaire
    [Show full text]
  • Medicated Skin Care Products– Draft
    2018-12-07 Throat Lozenges Monograph Health Products and Food Branch 1 2018-12-07 FOREWORD This monograph is intended to replace the existing Throat lozenges Monograph of January 13, 1995. This monograph describes the requirements necessary to receive market authorization [i.e. a Drug Identification Number (DIN) or a Natural Product Number (NPN)], for throat lozenges products. The monograph identifies the permitted medicinal and non-medicinal ingredients, concentrations, indications, directions and conditions of use for these products to be market authorized without the submission to Health Canada of additional evidence. It also may contain the test methods recommended to be used to comply with the requirements of this monograph. Products which do not meet the criteria outlined in this document can apply for market authorization outside of the monograph stream. Applicants are reminded that throat lozenges products, like other non-prescription drugs or natural health products, are subject to the Food and Drug Regulations or the Natural Health Products Regulations administered by the Natural and Non-prescription Health Products Directorate (NNHPD). This includes requirements related to labelling, manufacturing and product specifications. Additional information on labels, outside of those specified in the monograph, such as additional directions for use and/or non-therapeutic claims are acceptable as long as they meet the Guidelines for the Nonprescription and Cosmetic Industry Regarding Non-therapeutic Advertising and Labelling Claims, the Guidelines for Consumer Advertising of Health products for Nonprescription drugs, Natural Health Products, Vaccines and Medical Devices, and are not false, misleading or counterintuitive to the use of the product. The development of this monograph is the result of a thorough review of existing regulations, guidance documents, policies and current practices within Health Canada and other leading regulatory agencies.
    [Show full text]
  • Assessment of Spermicides by a Stripping Technique Against Human
    Assessment of spermicides by a stripping technique against human spermatozoa Janet Brotherton Department of Gynaecological Endocrinology, Sterility and Family Planning, Klinikum Steglitz of the Free University Berlin, Hindenburgdamm 30,1000 Berlin 45, Germany Summary. Fifty-two (52) compounds were tested for spermicidal activity by titration against human spermatozoa. The gradual decrease in mean sperm size was measured against increasing concentration of spermicide and the end-point was taken as the point at which all the peripheral cytoplasm had been removed and only the sperm core of nucleus and tail fibres remained. There were 14 compounds that produced this total effect. All were detergents, of various types, and the effect was purely physical. The most potent compounds caused complete stripping at 0\m=.\5\p=n-\50pmol/cell and most are already used in spermicidal preparations. A further 11 compounds, including sodium hypochlorite and some phenols, caused partial stripping, while 4 compounds caused sperm swelling. The test was not suitable for assessment of metabolic cell poisons. Introduction The methods of assessment and the types of potent spermicides have been reviewed by Bernstein (1974). The usual method of measuring the cytotoxic potencies of compounds against specific cell types is to measure the degree of inhibition of growth, i.e. of cell division. This method cannot be used to assess the potency of spermicides and it has been usual to measure some morphological or biochemical sperm characteristic as the end-point, e.g. the decrease in percentage of motile sperma¬ tozoa after a set time or the time taken for all the spermatozoa to become immotile.
    [Show full text]
  • Update on FDA Final Rule for Consumer Antiseptic Hand Wash Products Background: the U.S
    888-225-3267 / www.bestsanitizers.com PO Box 1360, Penn Valley, CA 95946 Update on FDA Final Rule for Consumer Antiseptic Hand Wash Products Background: The U.S. Food and Drug Administration (FDA) has published its Final Rule for consumer antiseptic hand wash products. This final rule applies to consumer antiseptic wash products that are intended for use with water and are rinsed off after use, including hand washes and body washes. It does not impact consumer hand sanitizer/rub/wipes used without water, healthcare antiseptics used with or without water, foodhandler antiseptics used with or without water, or first aid antiseptics. Those rules are expected in coming years. The Rule states consumer antiseptic wash products are “intended for use with water by the general population in home or public settings on a frequent or daily basis”, including products used in institutional settings. The FDA further elaborates in postings that this rule applies to products used in homes, schools, daycares, or other public settings and which are typically sold in retail establishments. The FDA has yet to clarify if consumer use for home healthcare may be allowed under other rulemaking. As the FDA was not provided sufficient safety and efficacy data, and certain data suggest there may be potential risks, Consumer Antiseptic Handwash products with one or more of the following active ingredients must be removed from the market or reformulated to remove these ingredients by September 6, 2017: - Triclosan - Nonylphenoxypoly (ethyleneoxy) ethanoliodine - Triclocarban
    [Show full text]
  • CATEGORY IV MONOGRAPH Throat Lozenges
    CATEGORY IV MONOGRAPH Throat Lozenges I) Description: This monograph applies to products in lozenge form intended to be dissolved in the mouth to help relieve sore throats. The medicinal ingredients, their concentrations and combinations in Category IV products are restricted to those specified in this monograph. The medicinal ingredients must be identified on product labelling by the names given in this monograph. II) Pharmaceutical Quality: a) All ingredient (medicinal and nonmedicinal) and finished product specifications should as a minimum meet the standards described in the publications referred to in Schedule B to the Food and Drugs Act, or equivalent standards. Where no Schedule B monograph exists for the dosage form, specifications should be similar to those of a comparable compendial dosage form. In the absence of a Schedule B standard for any dosage form, testing must be adequate to demonstrate the product's identity, potency, purity and quality. b) Special Notes: Finished product specifications should include tests for identification and an assay with suitable limits for the medicinal ingredient(s) including its components. The specifications for all dosage forms should include a description of the dosage form including organoleptic properties as well as physico-chemical testing e.g., pH, specific gravity, viscosity, appropriate to the dosage form. Where antimicrobial preservatives are added, an assay with suitable limits should be included. It is recommended that antimicrobial preservative effectiveness be determined in order to establish that the product is capable of resisting microbial contamination. III) Ingredients: a) Single Medicinal ingredients: Analgesic/Anaesthetic Ingredients: i) menthol 2 - 20 mg1 ii) phenol 10 - 50 mg iii) hexylresorcinol 2 - 4 mg iv) benzocaine 2 - 15 mg v) dyclonine hydrochloride 1 - 3 mg Drugs Directorate Throat Lozenges.
    [Show full text]
  • Safety and Effectiveness for Health Care Antiseptics; Topical
    DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Safety and Effectiveness for Health Care Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record Docket No. FDA-2015-N-0101 Preliminary Regulatory Impact Analysis Initial Regulatory Flexibility Analysis Unfunded Mandates Reform Act Analysis Economics Staff Office of Planning Office of Policy, Planning, Legislation, and Analysis Office of the Commissioner 1 Preface: Executive Summary of the Proposed Rule I. Introduction and Summary A. Introduction B. Summary of Costs and Benefits II. Preliminary Regulatory Impact Analysis A. Brief History of Health Care Antiseptics B. Background C. Need for Regulation D. Purpose of This Rule E. Baseline Conditions 1. Number of Active Ingredients and Affected Products In The Current Market for Health Care Antiseptics 2. Antiseptic Active Ingredient Usage in Health Care Antiseptic Products F Benefits 1. Benefits Assuming No Antiseptic Active Ingredient Is Demonstrated To Be GRAS/GRAE for Use In Health Care Antiseptic Products a. Reducing Resistant Microbial Strains b. Reducing Adverse Health Effects of Antiseptic Usage c. Reducing Infections Associated Withc Using Non-GRAS/GRAE Health Care Antiseptics 2. Benefits Assuming Every Antiseptic Active Ingredient With Large Market Share Is Demonstrated To Be GRAS/GRAE for Use In Health Care Antiseptic Products 3. Summary of Total Benefits G Costs 1. Reformulation and Relabeling 2 2. Testing a. GRAE Testing b. GRAS Testing 3. Exiting the Market 4. Costs Assuming Every Ingredient With Large Market Share Is Demonstrated To Be GRAS/GRAE for Use In Health Care Antiseptic Products 5.
    [Show full text]